ALNY stock forecast, quote, news & analysis
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics... Show more
Why Alnylam Pharmaceuticals (ALNY) Stock Is Down -29.6% in the Last 30 Days
Key Takeaways
- Alnylam Pharmaceuticals (ALNY) shares plunged approximately 29.6% over the past 30 days, falling from $312.78 on July 2 to $220.33 as of the latest close on August 3, 2026.
- The primary catalyst was the company's July 30 Q2 2026 earnings report, which featured a $200 million cut to full-year TTR product revenue guidance, triggering a single-day selloff of roughly 28%.
- Earlier in July, the failure of a rival therapy from AstraZeneca — eplontersen in the CARDIO-TTRansform trial — raised concerns about Alnylam's own nucresiran program and contributed to the stock's downward momentum.
- Amvuttra crossed $1 billion in quarterly revenue for the first time, yet management acknowledged that second-line demand growth had normalized faster than expected after an initial wave of pent-up patient transitions.
- Multiple securities law firms launched investigations into whether the company adequately disclosed the pace of its ATTR-CM launch trajectory, while Raymond James upgraded the stock to Strong Buy, citing an attractive risk/reward profile.
Alnylam Pharmaceuticals (ALNY) Company Overview and Market Position
Alnylam Pharmaceuticals is the pioneering leader in RNA interference (RNAi) therapeutics, a field built on Nobel Prize-winning science. Headquartered in Cambridge, Massachusetts, the company has translated over two decades of research into six approved medicines available in more than 70 countries. Its flagship product, Amvuttra (vutrisiran), targets transthyretin-mediated amyloidosis (ATTR) and has become the centerpiece of Alnylam's commercial strategy following its 2025 launch in the broader ATTR cardiomyopathy (ATTR-CM) indication. Alnylam also markets GIVLAARI and OXLUMO for rare genetic diseases, while advancing a deep pipeline spanning Huntington's disease, Alzheimer's, hypertension, and bleeding disorders. Investors closely track ALNY as a high-growth biopharma name with blockbuster revenue potential, balanced against the execution risks inherent in drug launches and clinical trials.
Alnylam Pharmaceuticals (ALNY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALNY shares experienced a sharp decline of approximately 29.6%, tumbling from a closing price of $312.78 on July 2, 2026, to $220.33 on August 3. The selling was concentrated around two key events: a competitor trial failure in early July that rattled confidence in the broader ATTR silencing approach, and a disappointing Q2 earnings report on July 30 that erased more than 28% of the stock's value in a single session. The quarterly trend paints an equally challenging picture, with the stock extending losses from earlier in 2026. ALNY had already retreated substantially from its 52-week high of $495.55 reached in October 2025, as valuation compression and a March 2026 Jefferies downgrade weighed on sentiment. The July guidance cut accelerated the decline, pushing shares near their 52-week low of $197.81 before a modest bounce into early August.
What Drove ALNY Stock Price in the Last 30 Days
The most consequential event of the past month was Alnylam's second-quarter 2026 earnings release on July 30. While the company posted adjusted earnings per share of $1.84 — beating the $1.60 consensus — total revenue of $1.29 billion missed the $1.32 billion estimate. More critically, management lowered its full-year 2026 TTR product revenue guidance to a range of $4.2 billion to $4.5 billion, down $200 million at the midpoint from its prior forecast of $4.4 billion to $4.7 billion. CFO Jeff Poulton acknowledged that the original guidance "didn't get it right," explaining that early second-line demand growth in 2025 benefited significantly from pent-up demand from patients waiting for a new therapy, a dynamic that normalized sooner than anticipated in 2026. Shares cratered $81.14 to close at $205.48 on July 30. Earlier in the month, the disappointing top-line results from AstraZeneca's CARDIO-TTRansform trial of eplontersen — an antisense oligonucleotide targeting the same TTR pathway — created a volatile trading environment. ALNY initially spiked on the competitive read-through before reversing sharply as investors questioned whether Alnylam's own Phase III TRITON-CM study of nucresiran could face similar headwinds in patients on heavy background therapy. Multiple analyst actions followed: RBC Capital lowered its price target to $350 from $445 while maintaining an Outperform rating; H.C. Wainwright reiterated a Buy rating with a $485 target; and on August 3, Raymond James upgraded ALNY to Strong Buy with a $420 price target, arguing the stock was trading near pessimistic net-present-value levels. Meanwhile, law firms including Kirby McInerney LLP, Bronstein, Gewirtz & Grossman LLC, and Schall, Brown & Schwartz LLP announced securities fraud investigations focused on whether the company adequately disclosed ATTR-CM launch dynamics.
What Drove ALNY Stock Performance Over the Last Quarter
The broader quarterly decline reflects a convergence of multiple headwinds that gradually eroded investor confidence. Alnylam entered the quarter with elevated expectations following a strong 2025 launch of Amvuttra in ATTR-CM, but valuation pressures were already mounting. A March 2026 downgrade from Jefferies — shifting from Buy to Hold with a $330 target — framed the stock as "priced for perfection," and the shares never fully recovered their momentum. A proxy filing in April highlighting substantial performance-tied equity awards added governance-related scrutiny. Against this backdrop, the normalization of second-line patient volumes and the Q2 guidance revision crystallized fears that the ATTR-CM opportunity, while still substantial with roughly 80% of the estimated 200,000-patient population untreated, may require a longer adoption curve than initially modeled. The competitive landscape also evolved: the CARDIO-TTRansform failure removed a potential rival but simultaneously raised the stakes for Alnylam's TRITON-CM trial. On the positive side, Amvuttra continued to demonstrate category-defining metrics — quarterly revenue exceeding $1 billion for the first time, first-line starts accounting for approximately 80% of new patient initiations, and adherence rates above 90%. The delayed U.S. generic entry for Pfizer's tafamidis until mid-2031 also provides a longer competitive runway.
Trending AI Robots
In periods of elevated volatility and sharp sector rotation, traders increasingly turn to AI-powered tools to help navigate fast-moving markets. Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots drawn from a broader ecosystem of hundreds of automated strategies trading thousands of tickers. The bots featured in this section are those demonstrating the strongest recent performance and highest relevance to current market conditions — spanning strategies that range from short-term swing trading to longer-term trend following, and covering equities, ETFs, and crypto markets. Each bot is built on distinct technical and fundamental logic, with transparent performance metrics and real-time trade signals. For investors seeking data-driven approaches to complement their own analysis, the Trending AI Robots page offers a window into how machine learning and pattern recognition are being applied to today's most dynamic trading environments.
ALNY Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several catalysts will shape ALNY's trajectory. The presentation of full CARDIO-TTRansform data and Alnylam's TRITON-CM Phase III enrollment and design updates — particularly at the upcoming European Society of Cardiology congress — will be closely scrutinized for signals about nucresiran's probability of success. Investors will also monitor quarterly TTR prescription trends for evidence that first-line demand growth can offset the normalization in second-line volumes. The company's pipeline milestones, including initial Phase I Huntington's disease data for ALN-HTT02 at EHDN in October and Phase II readouts across the rare disease portfolio, could shift the narrative beyond the TTR franchise. Regulatory developments, the outcome of the securities investigations, and the evolving competitive dynamics in the ATTR-CM market — including Pfizer's entrenched tafamidis position and emerging candidates from Ionis Pharmaceuticals — remain critical variables. Alnylam's $3.3 billion cash position provides substantial financial flexibility, but the path to restoring investor confidence will depend on consistent commercial execution and clinical data that validate the company's RNAi platform beyond its current approved indications.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALNY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 30, 2026
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 34 cases where ALNY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on July 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
ALNY moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.624) is normal, around the industry mean (20.354). P/E Ratio (39.847) is within average values for comparable stocks, (25.057). Projected Growth (PEG Ratio) (0.435) is also within normal values, averaging (3.600). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (6.605) is also within normal values, averaging (411.278).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology